SCHEMBL19737482

SCHEMBL19737482

COc1ccc(-c2cn(S(=O)(=O)c3ccccc3)c3c2C(=O)C(=O)C=C3)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELAVL1 Q15717 7/20 0.77
MAPT P10636 3/20 0.45
TSHR P16473 1/20 0.45
RAB9A P51151 1/20 0.45
HTR6 P50406 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PTGS2 P35354 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CTSG P08311 1/20 0.40
CMA1 P23946 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
LMNA P02545 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19737487 0.88 ELAVL1 (0.72) ELAVL1HTR6MEN1KMT2APOLB
SCHEMBL19737490 0.88 ELAVL1 (1.00) ELAVL1MAPTTSHRHTR6MEN1
Dimethylamine SCHEMBL21222569 0.85 ELAVL1 (0.90) ELAVL1HTR6L3MBTL1PTGS2
SCHEMBL22130714 0.84 ELAVL1 (0.83) ELAVL1HTR6MEN1KMT2AL3MBTL1
SCHEMBL19737425 0.82 ELAVL1 (0.83) ELAVL1MAPTHTR6POLBL3MBTL1
SCHEMBL22130675 0.80 ELAVL1 (0.92) ELAVL1MAPTRAB9AHTR6MEN1
SCHEMBL21222486 0.80 ELAVL1 (1.00) ELAVL1MAPTHTR6L3MBTL1PTGS2
SCHEMBL22130634 0.80 ELAVL1 (0.83) ELAVL1HTR6L3MBTL1PTGS2ALDH1A1
SCHEMBL22130724 0.79 ELAVL1 (1.00) ELAVL1MAPTTSHRRAB9AHTR6
SCHEMBL22130693 0.79 ELAVL1 (0.81) ELAVL1MAPTHTR6L3MBTL1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2020-06-23 US disclosed
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2019-08-08 US disclosed
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI TRENTO (IT) 2019-08-08 US disclosed
WO-2017216732-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY UNIVERSITA' DEGLI STUDI DI MILANO (IT) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241516-A1 AZA-TANSHINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY AZI2, TPMT, TYMS ELAVL1 2765/4885MAPT 4359/4885TSHR 3299/4885
US-10689342-B2 Aza-tanshinone derivatives, process for their preparation and their use in therapy AZI2, TPMT, TYMS ELAVL1 2765/4885MAPT 4359/4885TSHR 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.